Study pembrolizumab plus olaparib for stomach cancer after treatment
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 study tests whether combining pembrolizumab (an immunotherapy) with olaparib (a targeted cancer pill) can shrink or control recurrent or advanced stomach and GEJ cancer. You may be eligible if your cancer has already been treated with trastuzumab and certain body-function and blood/vital checks look safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and you’re at least 19 years old
- Your cancer has spots doctors can measure or assess on scans (measurable/evaluable lesions)
- Your overall health is good: you can do most self-care (ECOG 0–1)
- Your organs look strong enough for treatment (blood, kidney, liver) and you have at least 3 months to live
- You can swallow and keep pills down, and your heart pumping is adequate (LVEF 50% or higher)
- If your cancer is HER2-positive, you already had and failed first-line trastuzumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Hear when a new Gastric Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.